The Platform for Interdisciplinary Cardiovascular-metabolic-neurovascular Diseases (PICMAN)
Sponsored by National University Hospital, Singapore
About this trial
Last updated 2 years ago
Study ID
PICMAN
Status
Recruiting
Type
Observational [Patient Registry]
Placebo
No
Accepting
21 to 70 Years
All
Trial Timing
Ended a year ago
What is this trial about?
Background Changes in metabolism and mitochondrial function appear to precede cardiac
dysfunction, with much evidence supporting metabolic dysregulation as one of the earliest
precursors of cardiovascular disease. We hypothesise that quantifiable metabolic
inflexibility may be representative of an individual in his/her silent, but high-risk
progression towards insulin resistance, diabetes and cardiovascular disease. The platform
for interdisciplinary cardiovascular-metabolic-neurovascular diseases (PICMAN) across
National University Health System (NUHS) is a pilot, prospective, multi-ethnic cohort
study in Singapore.
Through extensive phenotyping in a preventive cardiology cohort, the central aim is to
define the metabolic flexibility range in a cohort of individuals at elevated risk of
atherosclerotic cardiovascular disease, to correlate metabolic flexibility to measures of
cardiometabolic health, including diastolic dysfunction, coronary and cerebral
atherosclerosis, body fat distribution and severity of non-alcoholic fatty liver disease.
What are the participation requirements?
Inclusion Criteria
- Patients aged 21-70 at screening
- 10-year ASCVD risk > 5% measured by QRISK 3 calculator
Exclusion Criteria
- Established DM (Prior diagnosis, long term medications or HbA1c >=6.5)
- Established CVD, such as ischemic heart disease, cerebrovascular accident, heart failure, atrial fibrillation
- Pregnancy
- Known contraindications to CT scan, such as allergy to contrast